Citadel Advisors’s RESPONSE GENETICS, INC COMMON SHS (DELAWARE) RGDX Stock Holding History

Citadel Advisors’s Portfolio RGDX Stock Details RGDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-48,098	Closed	-$16K	–	9670
2015 Q2	$16K	Buy	48,098 +15,081	+46%	+$5.11K	﹤0.01%	8278
2015 Q1	$15K	Sell	33,017 -7,046	-18%	-$3.14K	﹤0.01%	8085
2014 Q4	$13K	Buy	40,063 +10,863	+37%	+$6K	﹤0.01%	8063
2014 Q3	$20K	Buy	29,200 +11,996	+70%	+$9.4K	﹤0.01%	7454
2014 Q2	$16K	Buy	+17,204	New	+$18K	﹤0.01%	7433

Citadel Advisors's RGDX Position: Q3 2015 in Review

Citadel Advisors sold out of RESPONSE GENETICS, INC COMMON SHS (DELAWARE) (RGDX) in Q3 2015, closing a stake of 48,098 shares — an estimated $16K sold.

Citadel Advisors first reported a position in RGDX in Q2 2014 and held it in 5 quarters. The position peaked at $20K in Q3 2014. 1 fund tracked by Wall St. Rank holds RGDX as of Q3 2015.

Citadel Advisors reported no remaining RESPONSE GENETICS, INC COMMON SHS (DELAWARE) position as of Q3 2015 after selling out during the quarter.
Citadel Advisors sold 48,098 RESPONSE GENETICS, INC COMMON SHS (DELAWARE) shares in Q3 2015, an estimated $16K.
Citadel Advisors first reported a position in RESPONSE GENETICS, INC COMMON SHS (DELAWARE) in Q2 2014 and held it in 5 quarters.
Citadel Advisors's RESPONSE GENETICS, INC COMMON SHS (DELAWARE) position peaked at $20K in Q3 2014.
1 fund tracked by Wall St. Rank held RESPONSE GENETICS, INC COMMON SHS (DELAWARE) as of Q3 2015.

Based on Citadel Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.